Inogen’s (INGN) Hold Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reissued their hold rating on shares of Inogen (NASDAQ:INGN) in a research note issued to investors on Wednesday morning,Benzinga reports.

Separately, StockNews.com lowered shares of Inogen from a “buy” rating to a “hold” rating in a research report on Wednesday, February 26th.

Inogen Trading Down 2.8 %

INGN stock traded down $0.20 during midday trading on Wednesday, reaching $6.84. The stock had a trading volume of 155,499 shares, compared to its average volume of 241,359. Inogen has a 52-week low of $6.40 and a 52-week high of $13.33. The company’s fifty day simple moving average is $8.51 and its 200 day simple moving average is $9.27. The company has a market cap of $183.91 million, a price-to-earnings ratio of -3.05 and a beta of 1.48.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. increased its position in Inogen by 2.7% during the third quarter. JPMorgan Chase & Co. now owns 896,106 shares of the medical technology company’s stock worth $8,692,000 after purchasing an additional 23,891 shares during the last quarter. Ameriprise Financial Inc. increased its holdings in shares of Inogen by 0.6% during the 4th quarter. Ameriprise Financial Inc. now owns 848,980 shares of the medical technology company’s stock worth $7,785,000 after buying an additional 5,148 shares during the last quarter. Bridgeway Capital Management LLC raised its position in shares of Inogen by 4.7% during the 4th quarter. Bridgeway Capital Management LLC now owns 631,230 shares of the medical technology company’s stock valued at $5,788,000 after buying an additional 28,517 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Inogen by 25.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 607,837 shares of the medical technology company’s stock valued at $5,574,000 after acquiring an additional 123,208 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in Inogen by 1.1% in the third quarter. Geode Capital Management LLC now owns 554,191 shares of the medical technology company’s stock worth $5,377,000 after acquiring an additional 5,921 shares during the period. Hedge funds and other institutional investors own 89.94% of the company’s stock.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.